BDO Midlands has provided financial/tax due diligence services to Clinigen and the group’s debt funders in connection with its $150m acquisition of US-based CSM group and its €7.5m acquisition of Geneva-headquartered Iqone Healthcare Group.
Based in Burton-on-Trent, AIM-listed Clinigen is a global pharmaceutical products and services group with a current market capitalisation in excess of £1bn.
Headquartered in the USA with operations in Belgium and Germany, CSM provides a wide range of clinical trial services, including packaging, labelling, warehousing and logistics. The acquisition strengthens Clinigen’s competitive positioning and breadth of service offering within its Clinical Trials division.
Based in Geneva, Switzerland with subsidiary operations in Italy, Germany, France and Spain, Iqone has extensive experience in the set up and delivery of Managed Access Programs. The acquisition adds capability to Clinigen’s Unlicensed and Commercial divisions, whilst also providing a platform to support and expand activities in mainland Europe.
Thank you to the BDO team for the work on these acquisitions; professional, timely and high quality as always. In particular, the flexible and value-add support provided throughout the transaction processes was greatly appreciated and underlines BDO’s position as a trusted adviser to the Clinigen group.
Martin Abell Chief Financial Officer, Clinigen Group Plc